Compare Invesco DB Oil Fund (DBO) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Oil Fund vs Merck & Co., Inc. — how do they compare? Invesco DB Oil Fund trades at $20.89, while Merck & Co., Inc. trades at $132.49 (market cap $321.77B). The key difference: Merck & Co., Inc. pays a 2.61% dividend while Invesco DB Oil Fund pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Invesco DB Oil Fund nearer its low. Which is the better fit depends on your goals.
| DBO | MRK | |
|---|---|---|
Sector | Commodities - Energy | Health |
52-Week High | $23.80 | $131.84 |
52-Week Low | $11.98 | $77.60 |
Market Cap | — | $321.77B |
Enterprise Value | — | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBO trades at $20.88, up 0.14% today, with a bullish technical signal driven by moving averages and neutral oscillators. Recent news highlights oil market volatility due to Middle East supply disruptions and OPEC demand forecast cuts. The stock lacks disclosed financial ratios, limiting fundamental clarity amid sector-wide data reliability concerns.
Outlook hinges on oil price stability and company-specific updates, with upside potential from supply shocks but risks from demand weakness and geopolitical uncertainty. Investors await earnings and guidance for valuation anchors.
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco DB Oil Fund
DBO provides exposure to WTI crude oil prices through futures contracts. It is designed for investors seeking a way to invest in the performance of the fossil fuel market without purchasing physical oil barrels.
Read more on DBO →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
